Showing 47 results
-
Media Release /The product of over 120 consultations with health care practitioners, the Novartis Pro Portal is a one-stop digital hub developed to provide tailored, real-time support in daily practice. Dorval…
-
Media Release /Newest treatment for lung cancer reinforces Novartis commitment to developing innovative therapies that improve outcomes for Canadians affected by advanced lung cancer Dorval, Quebec, June 8,…
-
Media Release /Kesimpta® is the first and only B-cell therapy for RRMS that can be administered by patients in the safety and convenience of their home Kesimpta® delivers superior efficacy with a favourable…
-
Media Release /Beovu® is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the loading phase with no compromise in efficacy. 1,2 While wet age-…
-
Media Release /In Canada, cardiovascular disease accounted for more than 52,000 deaths annually between 2015 and 20191 Almost 80% of deaths from cardiovascular disease are preventable2. Novartis is joining…
-
Media Release /Public reimbursement is effective October 20th and will apply for children with SMA following the recommendation from the Institut national d'excellence en santé et services sociaux Zolgensma is…
-
Media Release /This World Sight Day, Fighting Blindness Canada and the Canadian Council of the Blind have partnered with Novartis Canada to launch “All Eyes on You”, a campaign urging Canadians to lend their…
-
Media Release /Dorval, Quebec, October 13, 2021 — Novartis Pharmaceuticals Canada Inc. today announced that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent…
-
Media Release /Clinical trial will study new technology that tracks eye movement to assist diagnosis and monitor disease progression Dorval, Quebec, October 5, 2021 — Novartis Pharmaceuticals Canada Inc. (…
-
Media Release /The Biome Summit 2021 will help fuel debate, drive innovation and advance action on cardiovascular disease as a critical public health issue Montreal, Quebec, August 26, 2021 – Novartis…
